The panel included experts in medical oncology, radiation oncology, community oncology, as well as statisticians, health outcome researchers, and a cancer survivor who provided the patient’s perspective. It conducted a systematic review of literature published between January 2006 and September 2015 and identified 50 relevant studies. Overall survival and disease-free or recurrence-free survival were the outcomes of interest.

The guidelines described how the panel evaluated the studies and made recommendations for what practicing oncologists should look for when reviewing literature on the topic.

Continue Reading

“Practicing community oncologists should review the recommended tests for a particular clinical scenario and decide which one would be most useful to consider for their patient,” said Dr Harris.

“Of note, the panel of experts does not recommend more than one test for a specific scenario. For example, it is not appropriate to do both Oncotype Dx and Prosigna in the same patient with early stage, ER- and/or PR-positive node negative breast cancer.”

RELATED: Abiraterone Acetate Plus Prednisone Beneficial for Some With AR-positive, Triple-negative Breast Cancer

She suggested that providers discuss the paper with colleagues or at a journal club or tumor board. “There will be a Journal of Oncology Practice publication on the same topic coming out in the near future to further clarify the details in a user-friendly fashion.  In addition, patient materials will be developed,” she said.


  1. Harris LN, Ismaila N, McShane LM, et al. Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology Clinical Practice Guideline [published online ahead of print February 8, 2016]. J Clin Oncol.doi: 10.1200/JCO.2015.65.2289.
  2. Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007;25(33):5287-5312.